Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 1, 2001 - Issue 5
Submit an article Journal homepage
178
Views
46
CrossRef citations to date
0
Altmetric
Review

Recombinant antibodies for cancer diagnosis and therapy

Christelle Souriau CRC for Diagnostics at CSIRO Health Sciences and Nutrition, 343 Royal Parade, Parkville, Victoria, 3052, Australia. [email protected]
&
Peter J Hudson CRC for Diagnostics at CSIRO Health Sciences and Nutrition, 343 Royal Parade, Parkville, Victoria, 3052, Australia. [email protected]
Pages 845-855 | Published online: 23 Feb 2005

Bibliography

  • LITTLE M, KIPRIYANOY SM, LE GALL F, MOLDENJAUER G: Of mice and men: hybridoma and recombinant antibodies. Immuriol. Today (2000) 21:364–370.
  • HUDSON PJ: Recombinant antibodies: a novel approach to cancer diagnosis and therapy. Expert Opiri. Irivestig. Drugs (2000) 9:1231–1242.
  • WEINER LM, ADAMS GP: New approaches to antibody therapy. Oricogerie (2000) 19:6144–6151.
  • CHAMES P, BATY D: Antibody engineering and its applications in tumor targeting and intracellular immunization. FEMS Microbial. Lett. (2000) 189:1–8.
  • BORREBAECK CA: Antibodies in diagnostics - from immunoassays to protein chips. Immuriol. Today (2000) 21:379–382.
  • GHETIE MA, BRIGHT H, VITETTA ES: Homodimers but not monomers of Rituxan (chimeric anti-CD 20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood (2001) 97:1392–1398.
  • BEHR TM, BLUMENTHAL RD, MEMTSOUDIS S et al.: Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Chu. Cancer Res. (2000) 6:4900–4907.
  • TODOROVSKA A, ROOVERS RC, DOLEZAL 0, KORTT AA, HOOGENBOOM HR, HUDSON PJ: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. j Immuriol. Methods (2001) 248:47–66.
  • ••An important review that summarises thelatest designs and validation studies for multivalent antibodies that were produced as cancer-targeting reagents.
  • WU AM, YAZAKI PJ, TSAI SW et al.: High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Nati Acad. Sri. USA (2000) 97:495–500.
  • ADAMS GE SHALLER CC, CHAPPELL LL et al.: Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl. Med. Biol. (2000) 27:339–346.
  • TAHTIS K, LEE FT, SMYTH FE et al.: Biodistribution properties of (111)Indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3s193 diabody and F(abl (2) constructs in a breast carcinoma xenograft model. Chu. Cancer Res. (2001) 7:1061–1072.
  • YAZAKI PJ, WU AM, TSAI SW et al.: Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug. Chem. (2001) 12:220–228.
  • GOEL A, COLCHER D, BARAN OWSKA-KORTYLEWI CZ J et al.: Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. (2000a) 60:6964–6971.
  • ••This study is an important comparison inthe pharmacoltinetics of dimeric scFv and tetravalent scFv. Tetravalent scEvs exhibited better biodistribution than their dimeric counterpart confirming the importance of multivalency for cancer therapy and diagnosis.
  • CASEY JL, PEDLEY RB, KING DJ, GREEN AJ, YARRANTON GT, BEGENT RH: Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. Br j Cancer (1999) 81:972–980.
  • WILLUDA J, KUBETZKO S, WAIBEL R, SCHUBIGER PA, ZANGEMEISTER-WITTKE U, PLUCKTHUN A: Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. _J. Biol. Chem. (2001) 276:4385–4392.
  • TOMLINSON I, HOLLIGER P: Methods for generating multivalent and bispecific antibody fragments. Methods Erizymol. (2000) 326:461–479.
  • POWER BE, HUDSON PJ: Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging. j Immuriol. Methods (2000) 242:193–204.
  • LI SL, LIANG SJ, GUO N, WU AM, FUJITA-YAMAGUCHI Y: Single-chain antibodies against human insulin-like growth Factor I receptor: expression, purification, and effect on tumor growth. Cancer /mamma immunather. (2000) 49:43–52.
  • ROOVERS RC, VAN DER LINDEN E, DE BRUINE A1 ARENDS JW, HOOGENBOOM HR: In vitro characterisation of a monovalent and bivalent form of a fully human anti Ep-CAM phage antibody. Cancer Immunol. Immuriother. (2001b) 50:51–59.
  • McCALL AM, SHAHIED L, AMOROSO AR et al.: Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. j Immuriol. (2001) 166:6112–6117.
  • NIELSEN UB, ADAMS GP, WEINER LM, MARKS JD: Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. (2000) 60:6434–6440.
  • ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. (2001) 61:4750–4755.
  • ••This study focuses on small monovalentscEvs and demonstrates that very high affinity reagents can have impaired penetration from the vasculature into solid tumours. This study validates the theory that interstitial pressure and antigen density play important roles in tumour targeting.
  • SENEKOWITSCH-SCHMIDTKE R, SCHUHMACHER C, BECKER KF et al.: Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res. (2001) 61:2804–2808.
  • BUCHEGGER F, ROTH A, ALLAL A et al.: Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Ann. NY Acad. Sri. (2000) 910:263-269 (discussion 269–270).
  • CLARKE K, LEE FT, BRECHBIEL MW, SMYTH FE, OLD LJ, SCOTT AM: In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res. (2000) 60:4804–11.
  • WILLIAMS LE, WU AM, YAZAKI PJ et al.: Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm. (2001) 16:25–35.
  • FUJIOKA Y, ARANO Y, ONO M et al.: Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments. Bioconjug. Chem. (2001) 12:178–185.
  • SEGAL DM, WEINER GJ, WEINER LM: Introduction: bispecific antibodies. Immuriol Methods (2001) 248:1–6.
  • CARTER P: Bispecific human IgG by design. J. Immuriol Methods (2001) 248:7–15.
  • TAKEMURA S, ASANO R, TSUMOTO K et al.: Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng. (2000) 13:583–538.
  • SCHOONJANS R, WILLEMS A, SCHOONOOGHE S, LEOEN J, GROOTEN J, MERTENS N: A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomol Eng. (2001) 17:193–202.
  • SCHUHMACHER J, KAUL S, KLIVENYI G et al: Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/ anti-Ga chelate antibodies. Cancer Res. (2001) 61:3712–3717.
  • HILLAIRET DE BOISFERON M, RAGUIN 0, DUSSAILLANT M, ROSTENE W, BARBAT J, GRUAZ-GUYON A: Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens. Bioconjug. Chem. (2000) 11:452–460.
  • HONEYCHURCH J, TUTT AL, VALERIUS T, HEIJNEN IA, VAN DE WINKEL JG, GLENNIE MJ: Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood (2000) 96:3544–3552.
  • COCHLOVIUS B, KIPRIYANOV SM, STASSAR MJ et al.: Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. I Immuriol (2000a) 165:888–895.
  • KATZENWADEL A, SCHLEER H, GIERSCHNER D, WETTERAUER U, ELSASSER-BEILE U: Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anti-Cancer Res. (2000) 20:551–555.
  • MANZKE 0, TESCH H, BORCHMANN P et al.: Locoregional treatment of low-grade B-cell lymphoma with CD3x CD 19 bispecific antibodies and CD28 costimulation. I. Clinical Phase I evaluation. bit .j Cancer (2001) 91:508–515.
  • JUNG G, BRANDL M, EISNER W et al: Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. Cancer (2001a) 91:225–230.
  • WALLACE PK, KAUFMAN PA, LEWIS LD et al.: Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in viva J. Immuriol Methods (2001) 248:167–182.
  • ROBERT B, GUILLAUME E LUESCHER I, ROMERO E MACH JP: Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur. (2000) 30:3165–3170.
  • JUNG G, GROSSE-HOVEST L, KRAMMER PH, RAMMENSEE HG: Target cell-restricted triggering of the CD95 (AP0-1/Fas) death receptor with bispecific antibody fragments. Cancer Res. (2001b) 61:846–848.
  • WILLEMSEN RA, WEIJTENS ME, RONTELTAP C et al.: Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. (2000) 7:1369–1377.
  • GRIFFIN MD, HOLMAN PO, TANG Q et al: Development and applications of surface-linked single chain antibodies against T-cell antigens. j Immunol Methods (2001) 248:77–90.
  • COCHLOVIUS B, KIPRIYANOV SM, STASSAR MJ etal.: Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res. (2000b) 60:4336–4341.
  • HAISMA HJ, GRILL J, CURIEL DT et al.: Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. (2000) 7:901–904.
  • ISRAEL BF, PCIKLES RJ, SEGAL DM, GERARD RD, KENNEY SC: Enhancement of adenovirus vector Entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody. Viral. (2001) 75:5215–5221.
  • CAO Y, SURESH MR: Bispecific MAb aided liposomal drug delivery. I Drug Target (2000) 8:257–266.
  • KREITMAN RJ: Immunotoxins. Expert Opiri. Pharmacother. (2000) 1:117–129.
  • ROZEMULLER H, CHOWDHURY PS, PASTAN I, KREITMAN RJ: Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomorias exotoxiri. bit. j Cancer (2001) 92:861–870.
  • SCHINDLER J, SAUSVILLE E, MESSMANN R, UHR JW, VITETTA ES: The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. OM. Cancer Res. (2001) 7:255–258.
  • SIMEONOY A, MATSUSHITA M, JUBAN EA et al: Blue-fluorescent antibodies. Science (2000) 290:307–313.
  • CHESTER KA, BHATIA J, BOXER G et al.: Clinical applications of phage-derived sFys and sFy fusion proteins. Dis. Markers (2000) 16:53–62.
  • KEPPLER-HAFKEMEYER A, KREITMAN RJ, PASTAN I: Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. bah Cancer (2000) 87:6–94.
  • RIPPMANN JF, PFIZENMAIER K, MATTES R, RETTIG WJ, MOOSMAYER D: Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule. Biochem. J. (2000) 349:805–812.
  • ONDA M, WILLINGHAM M, WANG QC etal.: Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. Immuriol (2000) 165:7150–7156.
  • CASEY JL, COLEY AM, TILLEY LM, FOLEY M: Green fluorescent antibodies: novel in vitro tools. Protein Eng. (2000) 13:445–452.
  • HINK MA, GRIEP RA, BORST JW et al:Structural dynamics of green fluorescent protein alone and fused with a single chain Fy protein. _J. Biol. Chem. (2000) 275:17556–17560.
  • JEONG LEE H, PARDRIDGE WM: Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J. Drug Target (2000) 8:413–424.
  • BICKEL U, YOSHIKAWA T, PARDRIDGE WM: Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deify. Rev (2001) 46:47–79.
  • SHI N, PARDRIDGE WM: Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sri. USA (2000) 97:7567–7572.
  • ••Describes the novel and efficient use ofrecombinant antibodies with specificity to transferrin coupled to liposomes to deliver exogenous genes into the brain. These immunoliposomes constitute stable and very promising delivery systems.
  • XU X, CLARKE P, SZALAI G et al.: Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. (2000) 60:4475–4484.
  • THOR STRATEN P, GULDBERG P, SCHRAMA D et al.: In situ cytokine therapy: redistribution of clonally expanded T cells. Eur. j Immunol. (2001) 31:250–258.
  • •An important study reporting the use of antibody-1L2 fusions. T-cells activated by such fusions were able to recirculate and mediate eradication of distant tumour sites.
  • RUNYON K, LEE K, ZUBEREK K, COLLINS M, LEONARD JP, DUNUSSI-JOANNOPOULOS K: The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood (2001) 97:2420–2426.
  • MARSHALL KW, MARKS JD: Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. Immunother. (2001) 24:27–36.
  • ULLENHAG G, BIRD C, RAGNHAMMAR P et al.: Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Immunol. (2001) 99:65–74.
  • VITI F, NILSSON E DEMARTIS S, HUBER A, NERI D: Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol. (2000) 326:480–505.
  • CHAMES P, HUGTON SE, COULIE PG, UCHANSKA-ZIEGLER B, HOOGENBOOM HR: Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-Al-MAGE-Al from a nonimmunized phage-Fab library. Proc. Natl. Acad. Li. USA (2000) 97:7969–7974.
  • COOKE SP, BOXER GM, LAWRENCE L etal.: A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res. (2001) 61:3653–3659.
  • KOENDERMAN L, KANTERS D, MAESEN B et al.: Monitoring of neutrophil priming in whole blood by antibodies isolated from a synthetic phage antibody library. j Leukoc. Biol. (2000) 68:58–64.
  • HUIE MA, CHEUNG MC, MUENCH MO, BECERRIL B, KAN YW, MARKS JD: Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc. Natl. Acad. Li. USA (2001) 98:2682–2687.
  • SODERLIND E, STRANDBERG L, JIRHOLT P et al.: Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nature Biotechnol. (2000) 18:852–856.
  • HOOGENBOOM HR, CHAMES P: Natural and designer binding sites made by phage display technology. Immunol,. Today (2000) 21:371–278.
  • JESTIN JL, VOLIOTI G, WINTER G: Improving the display of proteins on filamentous phage. Res. ll/licrobiol. (2001) 152:187–191.
  • ROOVERS RC, VAN DER LINDEN E, DE BRUINE AP ARENDS JW, HOOGENBOOM HR: Identification of colon tumour-associated antigens by phage antibody selections on primary colorectal carcinoma. Eur. J Cancer (2001a) 37:542–549.
  • HEITNER T, MOOR A, GARRISON JL, MARKS C, HASAN T, MARKS JD: Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. j Immunol. Methods (2001) 248:17–30.
  • MOTTERSHEAD DG, ALFTHAN K, OJALA K, TAKKINEN K, OKER-BLOM C: Baculoviral display of functional scFy and synthetic IgG-binding domains. Biochem. Biophys. Res. Commun. (2000) 275:84–90.
  • IRVING RA, COIA G, ROBERTS A, NUTTALL SD, HUDSON PJ: Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. j Immunol. Methods (2001) 248:31–45.
  • HANES J, JERMUTUS L, PLUCKTHUN A: Selecting and evolving functional proteins in vitro by ribosome display. Methods Enzymol. (2000a) 328:404–430.
  • HANES J, SCHAFFITZEL C, KNAPPIK A, PLUCKTHUN A: Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nature Biotechnol. (2000b) 18:1287–1292.
  • ••Selection of antibody libraries in vitroresulted in one of the highest affinity reagents reported to date. This report validates the potential of ribosome display to obtain high affinity reagents.
  • WILSON DS, KEEFE AD, SZOSTAK JW: The use of mRNA display to select high-affinity protein-binding peptides. Proc. Natl. Acad. Sri. USA (2001) 98:750–755.
  • KEEFE AD, SZOSTAK JW: Functional proteins from a random-sequence library. Nature (2001) 410:15–18.
  • GIOVANNONI L, VITI E ZARDI L, NERI D: Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res. (2001) 29:E27.
  • DAUGHERTY PS, IVERSON BL, GEORGIOU G: Flow cytometric screening of cell-based libraries. j Immunol. Methods (2000) 243:211–227.
  • BODER ET, MIDELFORT KS, WITTRUP KD: Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sri. (2000) 97:10701–10715.
  • KIEKE MC, SUNDBERG E, SHUSTA EV, MARIUZZA RA, WITTRUP KD, KRANZ DM: High affinity T cell receptors from yeast display libraries block T cell activation by superantigens. j Mot. Biol. (2001) 307:305–315.
  • MOSSNER E, KOCH H, PLUCKTHUN A: Fast selection of antibodies without antigen purification: adaptation of the protein fragment complementation assay to select antigen-antibody pairs. j Mot. Biol. (2001) 308:115–122.
  • IRVING RA, HUDSON PJ: Proteins emerge from disarray. Nature Biotech. 18:932–933.
  • HOLT LJ, BUSSOW K, WALTER G, TOMLINSON IM: By-passing selection: direct screening for antibody-antigen interactions using protein arrays. Nucleic Adds Res. (2000) 28:E72.
  • ••An innovative method to identify antigen/antibody interactions using protein arrays. This method is likely to become one of the methods of choice for library screening as soon as the commercial array platforms become readily available.
  • SIEGEL RW, ALLEN B, PAVLIK P, MARKS JD, BRADBURY A: Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics. Mol. Biol. (2000) 302:285–293.
  • POWER BE, CAINE JM, BURNS JE et al.: Construction, Expression and Characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector for application in vivo imaging of a carcinoma xenograft model. Cancer Immunol. Immunother. (2001) 50:241–250.
  • GOEL A, COLCHER D, KOO J, BOOTH BJ, PAVLINKOVA G, BATRA SK: Relative position of the hexahistidine tag effects binding properties of a tumor-associated single-chain Fy construct. Biochim. Biophys. Acta (2000) 1519:13–20.
  • POWERS DB, AMERSDORFERP, POUL M et al.: Expression of single-chain Fv-Fc fusions in Pichia pastods. j Immunol. Methods (2001) 251:123–135.
  • CLYNES RA, TOWERS TL, PRESTA LG, RAVENTH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. (2000) 6:443–446.
  • WORM A, PLUCKTHUN A: Stability engineering of antibody single-chain Fy fragments. j Md. Biol. (2001) 305:89–1010.
  • BOTHMANN H, PLUCKTHUN A: The periplasmic Escherichia colipeptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of antibody fragments with and without cis-prolines. _J. Biol. Chem. (2000) 275:17100–17105.
  • NUTTALL SD, IRVING RA, HUDSON PJ: Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr. Pharmaceut. Biotech. (2001) 1:253–262.
  • OHNO S, MORI N, MATSUNAGA T: Antigen-binding specificities of antibodies are primarily determined by seven residues of VH. Proc. Nati Acad. Sri. USA (1985) 82:2945–2949.
  • DESMYTER A, DECANNIERE K, MUYLDERMANS S, WYNS L: Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. j Biol. Chem. (2001)
  • HUFTON SE, VAN NEER N, VAN DEN BEUKEN T, DESMET J, SABLON E, HOOGENBOOM HR: Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS Lett. (2000) 475:225–231.
  • SHUSTA EV, HOLLER PD, KIEKE MC, KRANZ DM, WITTRUP KD: Directed evolution of a stable scaffold for T-cell receptor engineering. Nature Biotechnol. (2000) 18:754–759.
  • OLLMAN SAPHIRE E, PARREN PW, BARBAS CF 3rd, BURTON DR, WILSON IA: Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr. D. Biol. Crystallogr. (2001) 57:168–171.
  • VAN DER LINDEN RH, DE GEUS B, FRENKEN GJ, PETERS H, VERRIPS CT: Improved production and function of llama heavy chain antibody fragments by molecular evolution. j Biotechnol. (2000) 80:261–270.
  • JIRHOLT P, STRANDBERG L, JANSSON B et al.: A central core structure in an antibody variable domain determines antigen specificity. Protein Eng. (2001) 14:67–74.
  • STEINBERGER P, SUTTON JK, RADER C, ELIA M, BARBAS CF 3rd: Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. j Biol. Chem. (2000) 275:36073–36078.
  • WANG Z, WANG Y, LIZ, LI J, DONG Z: Humanization of a mouse monoclonal antibody neutralizing TNF-alpha by guided selection. j Immunol. Methods (2000) 241:171–184.
  • BEIBOER SH, REURS A, ROOVERS RC et al.: Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. j Mol. Biol. (2000) 296:833–849.
  • GOEL A, AUGUSTINE S, BARAN OWSKA-KORTYLEWICZ J et Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using131I-labeled multivalent CC49 single-chain fvs. Clic]. Cancer Res. (2001) 7:175–184.
  • HEMACHANDRA S, KAMBOJ K, COPFER J, PIER G, GREEN LL, SCHREIBER JR: Human monoclonal antibodies against Pseudomortas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infect. Immun. (2001) 69:2223–2229.

Websites

  • ••Useful Internet sites for recombinant antibodies, scFy fragments and libraries:
  • http://www.path.cam.ac.uld- mrc7/ humanisation/antibodies.html (list of humanised antibodies)
  • http://www.mgen.uni-heidelberg.de/SD/ SDscFySite.html (antibody structures)
  • http://www.mrc-cpe.cam.ac.uldimt-doc (Vbase; human antibody sequences)
  • http://www.imgt.cnusc.fr:8104/ (International Immunoglobulin database)
  • http://www.antibodyresource.com (USA links and others)
  • http://www.morphosys.com/(HuCAL scFy library)
  • http://www.catplc.co.uld(CAT scFv library) http://www.dyax.com/(Dyax Fab library)
  • http://www.bioinvent.com/(BioInvent Ab library)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.